Spotlight On... France's Essilor invests in Israeli startup making eyeglasses that can refocus themselves; Medtronic starts major trial to make case for superDimension; Blood Centers of America adopt Intercept; and more...

Israeli startup Deep Optics is developing eyeglasses that can automatically refocus to assist those with presbyopia, or age-related difficulty focusing on nearby objects. It recently announced a $4 million VC in support of its lenses with a liquid crystal layer that enables a changeable refractive index (or "smart" eyeglasses, perhaps). Investors include French eyeglass company Essilor. More

@FierceMedDev: BD forms $500M JV with private equity firm Apax to house ailing respiratory biz. More | Follow @FierceMedDev

@VarunSaxena2: FDA loss in Vascular Solution off-label promotion case foreshadowed Amarin settlement. Story | Follow @VarunSaxena2

@EmilyWFierce: Biopharma, Republicans and doctors dig in for fight against new CMS cancer-drug cuts. Article | Follow @EmilyWFierce

> Medtronic ($MDT) has started a massive 2,500-patient international trial on the long-term impact of its superDimension navigation system in early detection of lung cancer and treatment. More

> Constant Therapy has raised $2 million in Series A funding to back its mobile app for brain rehabilitation, including the treatment of speech, language and cognitive disorders. More

> Blood Centers of America, which has almost 50 member blood centers, has done a five-year agreement with Cerus ($CERS) for its Intercept Blood System for platelets and plasma that reduces pathogens, even those that are unknown. More

Biotech News

@FierceBiotech: Strike 3: Struggling Xoma jettisons its lead drug after (another) PhIII failure. News | Follow @FierceBiotech

@JohnCFierce: Sarepta has a new date with an FDA AdCom for Duchenne drug eteplirsen. Article | Follow @JohnCFierce

> Could MedImmune be about to start paying its way for AZ? Article

> Experts: Drug trial disaster followed several missteps; new rules needed. More

Pharma News

@FiercePharma: Ceva makes strides toward animal health dominance with strong 2015 sales. More | Follow @FiercePharma

@EricPFierce: More biologics manufacturing capacity comes online in the US. Story | Follow @EricPFierce

@CarlyHFierce: AbbVie's $595M anti-inflammatory deal promises an even bigger battle for psoriasis share. News | Follow @CarlyHFierce

> In a welcome, surprising reversal, pharma's reputation among patients takes an upturn. Story

> Valeant settles the R&O lawsuit that touched off its specialty pharmacy woes. Report

CRO News

> 'Molecule to blame' in fatal French drug study. More

> Icon teams up with a nonprofit to help drive better patient outcomes. Report

> Data collection firm ERT is changing private equity hands. Story

> Swiss CRO PSI stretches its reach into Israel. Article

Pharma Manufacturing News

> Merck hands top manufacturing job to Sanat Chattopadhyay. Report

> Lupin finishes Gavis buy, giving it U.S. manufacturing beachhead. Story

> Bain-backed compounder QuVa gets slapped by FDA for plant failings. Article

> Pfizer expanding API plant in Australia. Item

Pharma Asia News

> Price pressure on drug sales in China accelerates in 2016. Report

> Japan's AMED names 8 projects for pre-designation orphan review. Item

> Carlyle-backed Meinian Onehealth snaps up Ciming for $415M. Story

> China FDA approves Roche's cervical test CINtec. More

> Challenged Benitec moves to get word out on hep B candidate. Article

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.